News Release 

Nanostics to develop a simple blood test to predict severe COVID-19 in SARS-CoV-2 patients

Nanostics is developing and validating a simple blood test to predict severity of COVID-19 disease in SARS-CoV-2 positive patients

Nanostics

IMAGE

IMAGE: ClarityDX COVID-19 logo. view more 

Credit: Nanostics Inc.

Edmonton, Alberta - Nanostics Inc., a diagnostic healthcare company that focuses on developing tests to determine a patient's disease risk, announced today plans to develop and validate ClarityDX COVID-19; a simple blood test to predict the severity of COVID-19 disease in patients.

Nanostics, in collaboration with the Canadian BioSample Repository (CBSR) at the University of Alberta and Century Clinical Research Institute (CCRI), a Florida based clinical research company experienced at clinical study recruitment, will be collecting patient samples in Canada and the USA. Nanostics' ClarityDX Platform technology will be used to accurately measure viral load along with other known immunological COVID-19 severity risk factors. The resulting blood test will use machine learning algorithms to determine the risk level of COVID-19 patients.

As countries rapidly increase their testing capabilities to be able to detect COVID-19 infected people, there remains a major unmet clinical need to determine which patients are at risk of developing severe COVID-19 outcomes and which patients will have mild symptoms. Nanostics' ClarityDX COV ID-19 test is designed to address this need.

"The COVID-19 pandemic is unprecedented, approximately 20% of the people infected with SARS-CoV-2 become critically ill and many of those people die from this disease," John Lewis, CEO of Nanostics said, "we're joining the fight against COVID-19 by using our ClarityDX technology to rapidly and accurately predict which COVID-19 patients are at risk for developing severe disease."

ClarityDX COVID-19 is expected to play a significant role in helping healthcare professionals rapidly identify which patients are most at-risk of developing severe COVID-19 disease. This novel test will provide physicians with a better tool to manage the care of COVID-19 patient and improve patient outcomes.

###

About the ClarityDX Platform

The ClarityDX technology is a novel biomarker platform that combines enumeration of viruses and virus-sized particles with patient clinical data using machine learning algorithms to generate disease predictions.

ClarityDX uses microflow cytometry to quantify millions of biomarkers in a single sample. Advanced machine learning is then applied to accurately interpret this vast amount of data, providing a rapid and precise result.

About Nanostics Inc.

Nanostics is a privately held company focused on the development and commercialization of minimally invasive diagnostic tests. The Nanostics ClarityDX platform and analysis is set to transform the diagnostic landscape by bringing clarity to disease management. Website: http://www.nanosticsdx.com

About Canadian BioSample Repository

The CBSR provides efficient and robust biosample processing, management, storage and retrieval infrastructure. We operate on a cost-recovery basis for investigator-initiated studies globally. Website: https://biosample.ca/about-us/virtual-tour

About Century Clinical Research Inc.

CCRI has over ten years of clinical research experience in multiple specialties, including hematology and oncology. Website: https://www.centuryclinical.com/century_clinical_research.html

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.